Quarterly report pursuant to Section 13 or 15(d)

NET LOSS PER SHARE (Tables)

v3.24.1.1.u2
NET LOSS PER SHARE (Tables)
3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Earnings per Shares, basic and diluted
The table below sets forth a reconciliation of the basic and diluted earnings per share (“EPS”) calculations for the three months ended March 31, 2024 and 2023:

Three Months Ended March 31,
($ in thousands, except share and per share amounts) 2024 2023
Numerator:
Net loss $ (17,587) $ (18,490)
Denominator:
Weighted average shares outstanding - basic 94,960,371  76,524,735
Effect of dilutive equity awards (1)
  — 
Weighted average shares outstanding - diluted 94,960,371  76,524,735 
Net loss per share:
Basic $ (0.19) $ (0.24)
Diluted $ (0.19) $ (0.24)

(1) Due to the Company’s net loss, all unvested equity awards and the private placement warrants are anti-dilutive. The dilutive convertible instruments of the Backstop Notes are out of the money.
Schedule of Diluted Shares Outstanding
Set forth in the table below is the number of securities not included in the computation of diluted shares outstanding because the effect would be anti-dilutive:
Three Months Ended March 31,
2024 2023
Grants of RSUs with service only (i.e., time-vesting) conditions 5,186,091  4,529,117 
Common stock issuable under the Backstop Notes 9,600,031  9,600,031 
Private placement warrants
272,779  272,779